Biofidelity presents lung reagents for liquid biopsies at the AMP Annual Meeting

Biofidelity has launched Aspyre Lung Reagents (research use only) for liquid biopsy samples. Aspyre Lung identifies established non-small cell lung cancer (NSCLC) biomarkers in both DNA and RNA from tissue and blood in a single straightforward, four-step workflow and runs on existing qPCR platforms, enabling simple integration into laboratories globally.

Data supporting the launch will be presented at the Association for Molecular Pathology (AMP) Annual Meeting & Expo November 19-23, 2024 in Vancouver, Canada.

Additionally, Biofidelity will host an Innovation Spotlight at the AMP Conference on November 22 at 12:40 PST presented by Dr. Jeff Gregg, Biofidelity Vice President of Medical Affairs, who will provide insight into Aspyre Lung as an alternative to NGS.

“Until now there has not been an alternative to next-generation sequencing (NGS) to provide fast, simple, decentralized testing for NSCLC biomarkers,” said Biofidelity Co-Founder and CEO Barnaby Balmforth, PhD. “Aspyre Lung’s best-in-class performance from tissue and blood coupled with its proven performance with challenging samples makes Simplified Genomic Profiling (SGP) via Aspyre Lung a game-changer for laboratories globally.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>